Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) reports a net loss of $9.6 million in Q4 2020. Its R&D expenses and G&A (General and Administrative) expenses are $5.6 million...
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has reported a net loss of $10.7 million in Q4 2019. Its cash and cash equivalents in 2019 are $70.1 million. According...